[Recorded Nov. 5, 2020]

The COVID-19 pandemic has highlighted a needs for non-invasive, remote approaches to patient care.

Learn how companies like Neuroelectrics are working to bring non-invasive brain stimulation into the home. In May, 2020, Neuroelectrics received FDA approval for a clinical trial of at-home brain stimulation therapy via telemedicine for patients with Major Depressive Disorder (MDD). An additional trial with Boston Children’s Hospital (IDE G160208) is already underway, studying the therapy for treatment-resistant epilepsy.

This nonaccredited educational webinar is provided for information only.